Literature DB >> 6434584

Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist.

F Massara, E Ghigo, S Goffi, G M Molinatti, E E Müller, F Camanni.   

Abstract

In five healthy young men, pretreatment with the cholinergic muscarinic antagonist pirenzepine (0.6 mg/kg iv) almost completely abolished the rise in plasma growth hormone (GH) elicited by an iv bolus injection of 1 microgram/kg human pancreatic GH-releasing factor 1-40 (hp-GRF-40). These data demonstrate that cholinergic receptor sites involved in GH-releasing mechanisms do not interact with GRF-secreting structures in the central nervous system. A mechanism mediated via hypothalamic release of somatostatin or, alternatively, a direct pituitary site of action, can be postulated for the blocking effect of pirenzepine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434584     DOI: 10.1210/jcem-59-5-1025

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 2.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

3.  Somatostatinergic tone in children on chronic haemodialysis and after renal transplantation.

Authors:  M Cappa; P del Balzo; G Rizzoni; S Benedetti; P Borrelli
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

4.  Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.

Authors:  S Grottoli; P Razzore; E Arvat; S E Oleandri; R Rossetto; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

5.  The paradoxical response of growth hormone (GH) to thyrotropin-releasing hormone (TRH) in constitutionally tall children involves a cholinergic pathway.

Authors:  E Arteaga; P Valenzuelaa; A Cattani; M del Valle
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

Review 6.  Determinants of GH resistance in malnutrition.

Authors:  Pouneh K Fazeli; Anne Klibanski
Journal:  J Endocrinol       Date:  2014-01-27       Impact factor: 4.286

7.  Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man.

Authors:  M Cappa; A Grossi; S Benedetti; F Drago; S Loche; E Ghigo
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

Review 8.  GH/IGF-I axis in anorexia nervosa.

Authors:  L Gianotti; F Lanfranco; J Ramunni; S Destefanis; E Ghigo; E Arvat
Journal:  Eat Weight Disord       Date:  2002-06       Impact factor: 4.652

9.  Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa.

Authors:  S Fassino; F Lanfranco; G Abbate Daga; V Mondelli; S Destefanis; G G Rovera; F Camanni; E Ghigo; E Arvat; L Gianotti
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

10.  Mutation analysis of the muscarinic cholinergic receptor genes in isolated growth hormone deficiency type IB.

Authors:  Ali Mohamadi; Marco Martari; Cindy D Holladay; John A Phillips; Primus E Mullis; Roberto Salvatori
Journal:  J Clin Endocrinol Metab       Date:  2009-05-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.